Liu Y C, Cheng D L, Liu C Y, de Garis S T, Lin H H, Hsieh T L, Yen M Y, Wang R S, Chen Y S
Department of Medicine, Veterans General Hospital-Kaohsiung, Taiwan.
Southeast Asian J Trop Med Public Health. 1992 Sep;23(3):514-9.
The objective of this open label, non-comparative study was to evaluate the efficacy and safety of fleroxacin 400mg administered orally once daily to patients with acute osteomyelitis and/or acute septic arthritis. Nineteen patients (10 males and 9 females) were evaluable for the analysis of clinical efficacy and safety. Of these, 7 (36.8%) had osteomyelitis and 12 (63.2%) had septic arthritis. Bacteriological cures were reported in 6 of 7 patients (85.7%) with osteomyelitis and in 8 of 11 patients (72.7%) with septic arthritis. The median duration of treatment for the clinical cures in osteomyelitis and septic arthritis were 29.5 days and 46 days respectively. The eradication rate for the most common pathogens, Salmonella enteritidis and Staphylococcus aureus were 77.7% and 80.0%, respectively. The clinical response was cure in 4 of 7 patients (57.1%) evaluable for osteomyelitis, and in 9 of 12 patients (75.0%) evaluable for septic arthritis at the three-month follow-up after treatment. Adverse reactions were minimal. It is concluded that fleroxacin appears to be an effective and safe in the treatment of acute osteomyelitis and acute septic arthritis.
这项开放性、非对照研究的目的是评估每日口服一次400毫克氟罗沙星对急性骨髓炎和/或急性化脓性关节炎患者的疗效和安全性。19例患者（10例男性和9例女性）可纳入临床疗效和安全性分析。其中，7例（36.8%）患有骨髓炎，12例（63.2%）患有化脓性关节炎。7例骨髓炎患者中有6例（85.7%）报告细菌学治愈，11例化脓性关节炎患者中有8例（72.7%）报告细菌学治愈。骨髓炎和化脓性关节炎临床治愈的中位治疗时间分别为29.5天和46天。最常见病原体肠炎沙门氏菌和金黄色葡萄球菌的根除率分别为77.7%和80.0%。在治疗后三个月的随访中，7例可评估的骨髓炎患者中有4例（57.1%）临床治愈，12例可评估的化脓性关节炎患者中有9例（75.0%）临床治愈。不良反应轻微。结论是氟罗沙星在治疗急性骨髓炎和急性化脓性关节炎方面似乎有效且安全。
